The Stelara biosimilar cliff is landing inside JNJ numbers exactly as the market had been told to expect, and the second quarter showed that the rest of the Innovative Medicine portfolio is holding the line well enough to absorb the damage. Worldwide sales reached $25.3B in the second quarter. Reported growth was 6.6%, with operational growth of 5.6%. Stelara alone shaved about 4.6 percentage points off that operational growth. The net result is that every other franchise combined to deliver roughly ten points of underlying momentum, the kind of offset a patent-cliff company can only produce if its replacement pipeline is genuinely taking share. The defining 2025-2026 story is no longer the cliff itself, but how cleanly the underlying franchises step into the void.
Shares trade near $271 against a fifty-two-week band that ends at $276 on the high side. That band brackets the Stelara-cliff-related drawdown and the subsequent re-rating as Tremfya and the oncology franchises demonstrated replacement-rate growth. The current price sits near the top of the trailing range, valuing the equity at roughly $654B in market capitalization. Management continues to return capital aggressively, with a $6.4B dividend payout and a $4.2B repurchase in the first half. The combination of a high-quality credit profile and an unbroken dividend streak is itself a scarcity premium that the price reflects. Average daily volume of roughly 7.8M shares places JNJ among the most-liquid large-cap healthcare equities globally, and the reported beta of 0.23 confirms the defensive character of the price action.
The quarter's strongest evidence for the bull thesis is the contrast between the Innovative Medicine segment operating margin and the optical earnings print. Innovative Medicine segment income before tax margin expanded to 38.1% in the second quarter. That compares with 36.5% a year earlier, even with $0.2B of restructuring layered in. Operating leverage on Tremfya and Darzalex more than offset the Stelara mix drag. The clearest counterargument is on the MedTech side, where the segment operating margin compressed to 13.2% from 14.1% as tariffs, Orthopaedics separation costs, and a step-up in research and development all landed at once. The forward variables the reader should track are Tremfya's continued share-gain trajectory in inflammatory bowel disease, the Orthopaedics separation timeline (eighteen to twenty-four months from the October 2025 announcement), and the cadence of remaining talc litigation payments against the $3.7B reserve. The valuation, sitting at roughly thirty-one times trailing earnings and twenty-two times forward, prices the Stelara reset as finished and the Orthopaedics spin as a near-term catalyst.